Ranolazine as a therapeutic agent for diabetic cardiomyopathy: reducing endoplasmic reticulum stress and inflammation in type 2 diabetic rat model
The results indicate that ranolazine protects against DCM by attenuating oxidative stress, ER stress, and inflammation. Its potential as a therapeutic agent for DCM warrants further investigation.
Authors
- S. Zahra Bathaie (ORCID: https://orcid.org/0000-0002-2529-045X)
- Matin Mohyadini
- Hamid Yaghooti (ORCID: https://orcid.org/0000-0002-7517-6807)
- Aghele Fahimi
Institutions
- Tarbiat Modares University (IR)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1186/s40360-025-00945-9
- Citations
- 2
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Tarbiat Modares University